Ocugen, Inc

$10.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.95 (+36.87%) Today
-$0.75 (-6.85%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Ocugen, Inc and other stocks, options, and ETFs commission-free!

About OCGN

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA. The listed name for OCGN is Ocugen, Inc. Common Stock.

CEO
Shankar Musunuri
Employees
16
Headquarters
Malvern, Pennsylvania
Founded
2013
Market Cap
2.21B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
29.63M
High Today
$11.95
Low Today
$7.62
Open Price
$8.07
Volume
95.88M
52 Week High
$18.77
52 Week Low
$0.17

OCGN Earnings

-$3.55
-$2.07
-$0.59
$0.89
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 26, Pre-Market

You May Also Like

FRGI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure